Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 99-3548319

RARE DISEASE ADVOCATES

Tax-exempt · LOS ANGELES, CA 90065

Financials

$124K$117K2024
Revenue Expenses · by fiscal year end
Financials of RARE DISEASE ADVOCATES by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990-EZ$123,833$116,608$7,225$7,225$0$7,225
Financial details: 990-EZ for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$3,750
Program service revenue
$120,083

Expenses

Compensation of officers, directors and key employees
$39,375
Salaries, compensation and benefits (total)
$39,375
Professional fees and payments to contractors
$3,000
Other expenses
$74,233
Program services (functional)
$109,799

Balance sheet and other

Total assets, start of year
$0
Total assets, end of year
$7,225
Total liabilities, end of year
$0
Net assets, end of year
$7,225
Cash, savings and investments
$6,164
Gross receipts
$123,833

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990-EZ for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensation
GEORGE YAGHMOURCEO/DIRECTOR40$39,375

Address and contacts

Address (IRS master file)
PO BOX 65731, LOS ANGELES, CA 90065-0731
Signed the 990-EZ
GEORGE YAGHMOUR, CEO
Phone
(877) 829-5500
Return prepared by
FOUMBERG JUNEJA ROCHER & CO PC

California records

California keeps its own records of charities and corporations. Search them by EIN 99-3548319 or by the name RARE DISEASE ADVOCATES.

Attorney General, Registry of Charities and Fundraisers
Registration status and filed reports (CT-TR-1, RRF-1)

Mission

AT RARE DISEASE ADVOCATES ORGANIZATION, OUR MISSION IS TO EMPOWER AND UPLIFT INDIVIDUALS IMPACTED BY RARE DISEASES. RARE DISEASE ADVOCATES IS A NON-PROFIT ORGANIZATION DEDICATED TO RAISING PROVIDER AWARENESS, PROVIDING PATIENT SUPPORT, AND ADVOCATING FOR BETTER RESOURCES AND RESEARCH FOR THOSE LIVING WITH RARE MEDICAL CONDITIONS.WE SERVE HEALTH CARE PROVIDERS AROUND THE COUNTRY BUT PRIMARILY FOCUSING ON SOUTHERN CALIFORNIA BY CONDUCTING EDUCATIONAL SEMINARS AND PROVIDING FINANCIAL SUPPORT TO RARE DISEASE PATIENTS. THERE ARE OVER TEN THOUSAND RARE DISEASES. RARE DISEASES ARE ESTIMATED TO AFFECT MORE THAN THIRTY MILLION PEOPLE IN THE UNITED STATES. EACH DISEASE MAY BE RARE INDIVIDUALLY, BUT PEOPLE WITH RARE DISEASES OFTEN FACE SIMILAR CHALLENGES. THESE CHALLENGES MAY INCLUDE ACCESSING INFORMATION, GETTING A DIAGNOSIS, AND FINDING RESOURCES.OUR ORGANIZATION'S THREE PRIMARY OBJECTIVES:RAISE AWARENESS, PROVIDE SUPPORT AND ADVOCATE FOR CHANGE

990-EZ for the year ended December 31, 2024

Program accomplishments

  • EDUCATIONAL CONFERENCE SERIES ON PNH AND MDS: FROM AUGUST TO NOVEMBER 2024, RARE DISEASE ADVOCATES LAUNCHED A SERIES OF EDUCATIONAL SEMINARSFOCUSED ON PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND MYELODYSPLASTIC SYNDROMES (MDS). EACHEVENT FEATURED A CLINICAL PRESENTATION LED BY A PHARMD AND MD TEAM, DELIVERED TO A TARGETED AUDIENCE OFHEALTHCARE PROFESSIONALS INCLUDING PHYSICIANS, FELLOWS, NURSE PRACTITIONERS, AND PHARMACISTS. THESESESSIONS EMPHASIZED DIAGNOSTIC CHALLENGES, DISEASE PROGRESSION, AND EMERGING TREATMENT STRATEGIES TOIMPROVE AWARENESS AND CLINICAL OUTCOMES FOR THESE RARE HEMATOLOGIC CONDITIONS. NOTABLY, FOLLOWING TWOOF THESE SESSIONS, ATTENDING PHYSICIANS REPORTED DIAGNOSING PATIENTS WITH ONE OF THE DISCUSSED RAREDISEASES, HIGHLIGHTING THE DIRECT CLINICAL IMPACT OF THE EDUCATION PROVIDED.
    Expenses $80,186 · grants $87,314
  • EDUCATIONAL CONFERENCE SERIES ON MYELOFIBROSIS, AML, AND BPDCN: THE FINAL EDUCATIONAL EVENT IN DECEMBER 2024 FOCUSED ON MYELOFIBROSIS (MF), ACUTE MYELOID LEUKEMIA(AML), AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN). LIKE PRIOR CONFERENCES, THE SESSION WAS PRESENTED BY A PHARMD AND MD TEAM TO A TARGETED AUDIENCE OF HEALTHCARE PROFESSIONALS INCLUDING PHYSICIANS, FELLOWS, NURSE PRACTITIONERS, AND PHARMACISTS. THE GOAL WAS TO PROVIDE EDUCATION ON THE LATEST TREATMENT STRATEGIES, IMPROVE DISEASE RECOGNITION, AND HIGHLIGHT PATIENT CARE CONSIDERATIONS SPECIFIC TO THESE RARE HEMATOLOGIC MALIGNANCIES.
    Expenses $19,657 · grants $32,768
  • ORGANIZATIONAL INFRASTRUCTURE DEVELOPMENT: IN ITS FOUNDATIONAL YEAR, RARE DISEASE ADVOCATES FOCUSED ON ESTABLISHING THE INTERNAL INFRASTRUCTUREREQUIRED TO SUPPORT LONG-TERM, MISSION-ALIGNED PROGRAMMING. THIS INCLUDED DEVELOPING AND LAUNCHINGTHE ORGANIZATION'S OFFICIAL WEBSITE, SETTING UP A DONATION PORTAL AND NONPROFIT BANK ACCOUNT, AND INITIATING PARTNERSHIPS WITH SEVERAL PHARMACEUTICAL SPONSORS. THESE EFFORTS LAID A STRONG GROUNDWORK FOROPERATIONAL EFFICIENCY, DONOR ENGAGEMENT, AND STRATEGIC GROWTH IN THE RARE DISEASE ADVOCACY SPACE.
    Expenses $9,956

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990-EZ on file
2023December 31, 2023May 15, 2024Check at the IRS

File the 2025 990-EZ for RARE DISEASE ADVOCATES

Due May 15, 2026 · e-filed with the IRS by 990.tax, an IRS-authorized e-file provider

IRS record

EIN
99-3548319
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (509(a)(2))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2024
Accounting year ends
December
Files
Form 990 or 990-EZ
Category (NTEE)
Health care (E70)
Assets (IRS master file)
$7,225
Income (IRS master file)
$123,833

Filing history

FormYear endedRevenueExpensesAssetsReturn
990-EZDecember 2024$123,833$116,608$7,225IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 99-3548319).

Questions about RARE DISEASE ADVOCATES

What is the EIN of RARE DISEASE ADVOCATES?
The employer identification number (EIN) of RARE DISEASE ADVOCATES is 99-3548319.
Is RARE DISEASE ADVOCATES tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2024.
Are donations to RARE DISEASE ADVOCATES tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does RARE DISEASE ADVOCATES file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of RARE DISEASE ADVOCATES due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did RARE DISEASE ADVOCATES last file with the IRS?
The latest return in the IRS public files is the 990-EZ for the year ended December 2024.
Who are the officers and directors of RARE DISEASE ADVOCATES?
The 990-EZ for the year ended December 31, 2024 lists 1 person; 1 received compensation from the organization, the highest $39,375 (GEORGE YAGHMOUR, CEO/DIRECTOR).
How much revenue does RARE DISEASE ADVOCATES have?
On its 990-EZ for the year ended December 31, 2024 it reported revenue of $123,833, expenses of $116,608 and total assets of $7,225 at year end.

Other nonprofits in LOS ANGELES

All nonprofits in LOS ANGELES · California · Health care